By CH Unnikrsihnan Drug maker and researcher Glenmark Pharmaceuticals Ltd's new biological drug candidate Bi-Specific ...

This week's report explores the pharmaceutical industry’s evolution toward resilient, scalable systems that prioritize ...

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Key market opportunities in the antibody optimization service industry include addressing rising chronic and complex diseases ...

NMPA accepts Akeso’s supplemental New Drug Application for gumokimab to treat active ankylosing spondylitis: Hong Kong Wednesday, January 21, 2026, 12:00 Hrs [IST] Akeso Inc, a ...

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...

Immunomic Therapeutics, Inc. ("ITI"), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA ...

The Astria acquisition introduces uncertainty for BioCryst. Read why I see no compelling reason to initiate a position in ...

Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...

BOSTON, Jan. 20, 2026) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of ...

EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...